SMT201500012B - 8-Cloro-3-pentil-3,7-diidro-1H-purin-2,6-dione 2-amine-2-(idrossimetil)-1,3-propandiolo anidrato peril trattamento di malattie - Google Patents

8-Cloro-3-pentil-3,7-diidro-1H-purin-2,6-dione 2-amine-2-(idrossimetil)-1,3-propandiolo anidrato peril trattamento di malattie

Info

Publication number
SMT201500012B
SMT201500012B SM201500012T SM201500012T SMT201500012B SM T201500012 B SMT201500012 B SM T201500012B SM 201500012 T SM201500012 T SM 201500012T SM 201500012 T SM201500012 T SM 201500012T SM T201500012 B SMT201500012 B SM T201500012B
Authority
SM
San Marino
Prior art keywords
anhydrate
dione
purine
propanediol
dihydro
Prior art date
Application number
SM201500012T
Other languages
English (en)
Italian (it)
Inventor
Holly Esken
Beth Adams Norton
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of SMT201500012B publication Critical patent/SMT201500012B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM201500012T 2008-12-08 2015-01-16 8-Cloro-3-pentil-3,7-diidro-1H-purin-2,6-dione 2-amine-2-(idrossimetil)-1,3-propandiolo anidrato peril trattamento di malattie SMT201500012B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12059608P 2008-12-08 2008-12-08
PCT/US2009/066941 WO2010068581A1 (en) 2008-12-08 2009-12-07 Novel compounds

Publications (1)

Publication Number Publication Date
SMT201500012B true SMT201500012B (it) 2015-05-03

Family

ID=42243044

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500012T SMT201500012B (it) 2008-12-08 2015-01-16 8-Cloro-3-pentil-3,7-diidro-1H-purin-2,6-dione 2-amine-2-(idrossimetil)-1,3-propandiolo anidrato peril trattamento di malattie

Country Status (22)

Country Link
US (3) US9163024B2 (el)
EP (1) EP2370440B1 (el)
JP (1) JP5666464B2 (el)
KR (1) KR101743783B1 (el)
CN (1) CN102245606B (el)
AU (1) AU2009324811B2 (el)
BR (1) BRPI0922134A2 (el)
CA (1) CA2746316C (el)
CY (1) CY1116032T1 (el)
DK (1) DK2370440T3 (el)
EA (1) EA020037B1 (el)
ES (1) ES2527354T3 (el)
HR (1) HRP20150026T1 (el)
IL (1) IL213032A (el)
MX (1) MX2011006022A (el)
PL (1) PL2370440T3 (el)
PT (1) PT2370440E (el)
RS (1) RS53777B1 (el)
SI (1) SI2370440T1 (el)
SM (1) SMT201500012B (el)
WO (1) WO2010068581A1 (el)
ZA (1) ZA201103397B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1781657B1 (en) 2004-02-14 2013-03-27 GlaxoSmithKline Intellectual Property Development Limited Medicaments with hm74a receptor activity
EP2272848B1 (en) 2005-08-10 2012-12-26 Glaxosmithkline LLC Xanthine derivatives as selective HM74A agonists
EP2854526B1 (en) * 2012-03-22 2018-04-25 vTv Therapeutics LLC Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657327A (en) * 1970-06-01 1972-04-18 Upjohn Co Prostaglandin salts of tris(hydroxymethyl)aminomethane
US4647585A (en) 1984-11-08 1987-03-03 E. R. Squibb & Sons, Inc. Bicycloheptane substituted ethers
WO2001043692A2 (en) * 1999-12-15 2001-06-21 Smithkline Beecham Corporation SALTS OF Cis-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID
US20030013905A1 (en) 2002-06-10 2003-01-16 Huang Guishu Kris Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid
EP1781657B1 (en) * 2004-02-14 2013-03-27 GlaxoSmithKline Intellectual Property Development Limited Medicaments with hm74a receptor activity
GB0423568D0 (en) * 2004-10-22 2004-11-24 Smithkline Beecham Corp Novel compounds
US20090209561A1 (en) 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
EP2272848B1 (en) 2005-08-10 2012-12-26 Glaxosmithkline LLC Xanthine derivatives as selective HM74A agonists
GB0516464D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds

Also Published As

Publication number Publication date
EA020037B1 (ru) 2014-08-29
AU2009324811A1 (en) 2011-06-23
IL213032A0 (en) 2011-07-31
EA201170783A1 (ru) 2011-12-30
US20110251218A1 (en) 2011-10-13
AU2009324811B2 (en) 2013-01-24
CN102245606A (zh) 2011-11-16
CA2746316C (en) 2017-01-03
CY1116032T1 (el) 2017-01-25
US9163024B2 (en) 2015-10-20
CA2746316A1 (en) 2010-06-17
BRPI0922134A2 (pt) 2015-08-18
PT2370440E (pt) 2015-01-14
PL2370440T3 (pl) 2015-05-29
CN102245606B (zh) 2014-08-20
ES2527354T3 (es) 2015-01-22
EP2370440A4 (en) 2012-05-30
ZA201103397B (en) 2012-01-25
HRP20150026T1 (hr) 2015-02-13
SI2370440T1 (sl) 2015-02-27
IL213032A (en) 2015-02-26
RS53777B1 (en) 2015-06-30
EP2370440B1 (en) 2014-11-12
US20150366870A1 (en) 2015-12-24
MX2011006022A (es) 2011-06-28
JP2012511028A (ja) 2012-05-17
KR101743783B1 (ko) 2017-06-05
KR20110097816A (ko) 2011-08-31
DK2370440T3 (en) 2014-12-08
JP5666464B2 (ja) 2015-02-12
US20170027945A1 (en) 2017-02-02
EP2370440A1 (en) 2011-10-05
WO2010068581A1 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
CY2017042I1 (el) Ενωσεις πυρρολοπυριμιδινης ως αναστολεις cdk
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
BR112014028395A2 (pt) derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer
DK2483255T3 (da) Oxazinderivater samt deres anvendelse ved behandling af neurologiske lidelser
DK2300443T3 (da) Triazolderivater, der er anvendelige til behandling af sygdomme
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
BRPI0718592A2 (pt) compostos heterocíclicos bicíclicos substituidos por 4-cianofenilamino como inibidores de hiv
BRPI0811065A2 (pt) Indazóis 5-heteroaril substituídos como inibidores de quinase
BRPI0718266A2 (pt) Compostos heterocíclicos como agentes anti-inflamatórios.
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
BRPI0916233A2 (pt) compostos heterocíclicos antivirais
BRPI0925059A2 (pt) Pirimidina substituída de compostos de purina como quinase(s) inibidoras.
ATE539070T1 (de) Heterozyklische antivirale verbindungen
BR112012008108A2 (pt) derivados de xantina substituídos
BRPI0914555A2 (pt) derivados de triazol bicíclicos para o tratamento de tumores
DK2114951T3 (da) Hidtil ukendte phosphodiesterase-inhibitorer
BRPI0821349A2 (pt) compostos antivirais heterocíclicos
BRPI0924121A2 (pt) compostos antivirais heterocíclicos
DK1993589T3 (da) Behandlinger for neurologiske sygdomme
IT1396213B1 (it) Tornio per lavorazione combinata
BRPI0910392A2 (pt) ferramenta de fresagem para usinagem de peças com remoção de aparas
BRPI0912433A2 (pt) classe de espiro piperidinas para o tratamento de doenças neurodegenerativas
SMT201500012B (it) 8-Cloro-3-pentil-3,7-diidro-1H-purin-2,6-dione 2-amine-2-(idrossimetil)-1,3-propandiolo anidrato peril trattamento di malattie
BRPI0913644A2 (pt) processo para a prepração de derivados de pirimidina substituída.
BRPI0909039A2 (pt) escareador